Asset profile
PF-05221304
Unknown / undisclosed
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
PF-05221304 is clesacostat, Pfizer's liver-targeted ACC inhibitor, developed for MASH alone and with ervogastat. Viking Therapeutics' FY2025 Form 10-K enumerates the competing MASH programmes it is aware of and now lists only 'ervogastat (PF-06865571) and PF-07853578 from Pfizer Inc.'; its FY2024 10-K had listed 'ervogastat (PF-06865571) and clesacostat (PF-05221304) from Pfizer Inc.' Pfizer's December 2025 out-licence to Madrigal covered ervogastat only, so clesacostat was left behind. Note for review: this is a competitor-filing pipeline diff, not an absence from a Pfizer-authored enumeration - Pfizer's own pipeline page paginates client-side and cannot be used for absence. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
30 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 30 same-indication; 13 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PF-05221304: this drug | Phase 2 | — | Acetyl-CoA carboxylase (ACC1/ACC2) | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Belapectin | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| GR-MD-02 | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| ALN-HSD | Phase 2 | RNA / oligonucleotide | HSD17B13 | ||
| ALN-PNP | Phase 2 | RNA / oligonucleotide | PNPLA3 |
…and 15 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.